Viridian Therapeutics
Enters commercial stage with Lumvoa, an intravenous IGF-1R antibody for thyroid eye disease.
$23.08
After-hours close−0.01 (−0.04%)
At close$23.09(−3.31%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.99 | — | — |
| Aug 2026 | −$1.03 | −$1.05 | −1.9% |
| Aug 2026 | −$1.02 | −$1.05 | −2.9% |
| May 2026 | −$1.06 | −$0.90 | +15.1% |
| Feb 2026 | −$0.90 | −$1.08 | −20.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Oct 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.99 | — | — | $4.0M | — | — |
| Aug 6, 2026 | −$1.03 | −$1.05 | −1.9% | $56.4K | $284.0K | +403.9% |
| Aug 5, 2026 | −$1.02 | −$1.05 | −2.9% | $30.5K | $284.0K | +829.8% |
| May 5, 2026 | −$1.06 | −$0.90 | +15.1% | $36.1K | $141.0K | +290.8% |
| Feb 26, 2026 | −$0.90 | −$1.08 | −20.0% | $18.4M | $132.0K | −99.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Nov 5, 2025 | ||||||
| Aug 6, 2025 | ||||||
| May 6, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 8, 2024 | ||||||
| Feb 27, 2024 | ||||||
| Nov 13, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 9, 2023 | ||||||
| Mar 8, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 15, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 10, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 11, 2021 | ||||||
| May 6, 2021 | ||||||
| Mar 25, 2021 | ||||||
| Nov 10, 2020 | ||||||
| Aug 5, 2020 | ||||||
| May 7, 2020 | ||||||
| Mar 11, 2020 | ||||||
| Nov 7, 2019 | ||||||
| Aug 7, 2019 | ||||||
| May 8, 2019 | ||||||
| Mar 13, 2019 | ||||||
| Nov 7, 2018 | ||||||
| Aug 7, 2018 | ||||||
| May 9, 2018 | ||||||
| Mar 14, 2018 | ||||||
| Nov 8, 2017 | ||||||
| Aug 11, 2017 | ||||||
| May 10, 2017 | ||||||
| Mar 24, 2017 | ||||||
| Oct 26, 2016 | ||||||
| Aug 15, 2016 | ||||||
| May 16, 2016 | ||||||
| Mar 16, 2016 | ||||||
| Nov 12, 2015 | ||||||